CardioCell Adds Stony Brook University To Sites Conducting A Phase...

Recruitment for 20 qualified patients is currently underway at only . More details on the study, entitled "Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology," is available at: "The Heart Institute of Stony Brook University Medical Center is ideally suited for CardioCell's chronic HF study," says Dr. and surrounding areas, and its state-of the-art labs are staffed by experts at handling live cells like the itMSCs used in this study's protocols."

http://ift.tt/1BnuiAq